Fresenius SE PE Ratio 2016-2024 | FSNUY
Current and historical p/e ratio for Fresenius SE (FSNUY) from 2016 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Fresenius SE PE ratio as of April 24, 2025 is 14.06.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Fresenius SE PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-04-24 |
11.39 |
|
103.55 |
| 2024-09-30 |
9.55 |
$0.11 |
86.83 |
| 2024-06-30 |
7.47 |
$-0.25 |
0.00 |
| 2024-03-31 |
6.75 |
$-0.03 |
0.00 |
| 2023-12-31 |
7.75 |
0 |
0.00 |
| 2023-09-30 |
7.80 |
$0.11 |
70.89 |
| 2023-06-30 |
6.92 |
$0.48 |
14.42 |
| 2023-03-31 |
6.53 |
$0.62 |
10.53 |
| 2022-12-31 |
6.77 |
$0.67 |
10.11 |
| 2022-09-30 |
5.20 |
$0.82 |
6.34 |
| 2022-06-30 |
7.30 |
$0.87 |
8.39 |
| 2022-03-31 |
8.72 |
$0.94 |
9.28 |
| 2021-12-31 |
9.47 |
$0.97 |
9.76 |
| 2021-09-30 |
11.32 |
$0.93 |
12.17 |
| 2021-06-30 |
12.27 |
$0.93 |
13.19 |
| 2021-03-31 |
10.30 |
$0.88 |
11.70 |
| 2020-12-31 |
10.68 |
$0.87 |
12.28 |
| 2020-09-30 |
10.50 |
$0.91 |
11.54 |
| 2020-06-30 |
11.20 |
$0.91 |
12.31 |
| 2020-03-31 |
8.41 |
$0.95 |
8.86 |
| 2019-12-31 |
12.73 |
$0.96 |
13.26 |
| 2019-09-30 |
10.57 |
$0.96 |
11.01 |
| 2019-06-30 |
12.27 |
$0.96 |
12.78 |
| 2019-03-31 |
12.42 |
$1.07 |
11.61 |
| 2018-12-31 |
10.77 |
$1.08 |
9.97 |
| 2018-09-30 |
16.33 |
$1.09 |
14.98 |
| 2018-06-30 |
17.85 |
$1.08 |
16.53 |
| 2018-03-31 |
16.77 |
$0.95 |
17.66 |
| 2017-12-31 |
17.17 |
$0.92 |
18.66 |
| 2017-09-30 |
17.73 |
$0.87 |
20.38 |
| 2017-06-30 |
18.81 |
$0.86 |
21.88 |
| 2017-03-31 |
17.56 |
$0.84 |
20.91 |
| 2016-12-31 |
17.08 |
$0.80 |
21.34 |
| 2016-09-30 |
17.40 |
$0.76 |
22.89 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$0.000B |
$23.628B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
